Erratum to: Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: Results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol in Chronic Heart Failure II (MAIN-CHF II) study (Heart Vessels DOI: 10.1007/s00380-013-0340-3);Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: Results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol in Chronic Heart Failure II (MAIN-CHF II) study

Heart and Vessels

Volumn 29, Issue 2, 2014, Pages 238-247

  Hori, Masatsugu ^a   Nagai, Ryozo ^b   Izumi, Tohru ^c   Matsuzaki, Masunori ^d  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bisoprolol; Carvedilol; Chronic heart failure; Japan; Left ventricular function; Randomized controlled trial

Indexed keywords

BISOPROLOL FUMARATE; CARVEDILOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART RATE; HOSPITAL ADMISSION; HUMAN; ISCHEMIC COLITIS; JAPANESE; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; TREATMENT DURATION; AGED; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; EARLY TERMINATION OF CLINICAL TRIAL; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; JAPAN; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; BISOPROLOL; CARBAZOLES; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HEART FAILURE; HEART RATE; HUMANS; JAPAN; MALE; MIDDLE AGED; PATIENT ADMISSION; PROPANOLAMINES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84897029234     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0373-7     Document Type: Erratum

References (24)

1. CIBIS-II Investigators (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II); a randomised trial. Lancet 353:9-13
2. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1355 (Pubitemid 26152713)
3. The MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007
4. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, Staiger C, Curtin EL, DeMets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658 (Pubitemid 32479962)
5. Brophy JM, Joseph L, Rouleau JL (2001) Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 134:550-560 (Pubitemid 32245316)
6. The Joint Study Group in 2009 of the Japanese Circulation Society (2010) Guidelines for diagnosis and treatment of cardiovascular diseases; guidelines for treatment of chronic heart failure (JCS 2010) (in Japanese). http://www.j-circ.or.jp/guideline/pdf/JCS2010-matsuzaki-h.pdf
7. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 119:e391-e479
8. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388-2442
9. Sasayama S (1990) Severity of heart failure. Curr Med 22:555-560
10. The Joint Study Group in 2003-2004 of the Japanese Circulation Society (2005) Guidelines for the clinical application of echocardiography. Circ J 69 (Suppl IV):1343-1408 (In Japanese)
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358-367
12. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150:784-794
13. Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Töpper A, Mehrhof F, Prettin C, Putniković B, Nešković AN, Krotin M, Sakač D, Lainščak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R (2011) Titration to target dose of bisoprolol vs carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 13:670-680
14. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA (2005) Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26:2259-2268 (Pubitemid 41541389)
15. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103:1428-1433 (Pubitemid 32220636)
16. Off-Label Drugs Review Meeting (2011) Non-approved and off-label drugs review meeting. Report on the validity of the application based on publicly known data - addition of chronic heart failure for bisoprolol fumarate (In Japanese). http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou-iryou/iyakuhin/ kaihatsuyousei/index.html
17. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S (2004) Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330 (Pubitemid 38176834)
18. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE (2010) Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 56:392-406
19. Feola M, Aspromonte N, Canali C, Ceci V, Giovinazzo P, Milani L, Quarta G, Ricci R, Scardovi AB, Uslenghi E, Valle R (2005) Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure. Am J Cardiol 96:705-709 (Pubitemid 41207318)
20. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-167 (Pubitemid 34764819)
21. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R (2002) B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105:2392-2397 (Pubitemid 34556391)
22. Antonopoulos GV, Lau J, Konstam MA, Udelson JE (1999) Are drug-induced changes in left-ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure? Circulation 100:I296
23. Konstam MA, Udelson JE, Anand IS, Cohn JN (2003) Ventricular remodeling in heart failure: a credible surrogate endpoint. J Cardiac Fail 9:350-353 (Pubitemid 37351801)
24. Konstam MA (2005) Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 96:867-871 (Pubitemid 41317667)